Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda as Chief Executive Officer and Member of the Board of Directors
Company actively advancing lead ophthalmology drug candidate to first Investigational New Drug (IND) filing
Company actively advancing lead ophthalmology drug candidate to first Investigational New Drug (IND) filing
1700 Owens Street, Suite 595
San Francisco, CA 94158
1200 Westlake Ave N, Suite 900
Seattle, WA 98109
© 2025 venBio. All Rights Reserved.